INT87139

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2000
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 18
Total Number 18
Disease Relevance 10.65
Pain Relevance 7.76

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Il6) extracellular region (Il6)
Anatomy Link Frequency
plasma 2
fibroblasts 2
lung 2
body 2
neutrophil 2
Il6 (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 223 100.00 Very High Very High Very High
Morphine 78 100.00 Very High Very High Very High
Neuropathic pain 7 100.00 Very High Very High Very High
Thermal hyperalgesia 5 99.44 Very High Very High Very High
ketamine 22 99.24 Very High Very High Very High
Inflammation 314 99.04 Very High Very High Very High
Brush evoked pain 6 98.44 Very High Very High Very High
fibrosis 3 96.28 Very High Very High Very High
Hippocampus 15 96.00 Very High Very High Very High
Inflammatory mediators 6 94.40 High High
Disease Link Frequency Relevance Heat
Cancer 48 100.00 Very High Very High Very High
Necrosis 20 100.00 Very High Very High Very High
Neuropathic Pain 14 100.00 Very High Very High Very High
Parkinson's Disease 13 100.00 Very High Very High Very High
Body Weight 4 100.00 Very High Very High Very High
Hyperalgesia 7 99.44 Very High Very High Very High
INFLAMMATION 247 99.04 Very High Very High Very High
Cv General 3 Under Development 4 98.96 Very High Very High Very High
Cognitive Disorder 38 97.48 Very High Very High Very High
Disease 135 97.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RT-PCR experiments demonstrated that U50,488 treatment significantly reduced the LPS-mediated increase in IL-6 mRNA and that this effect was also blocked by nor-BNI.
Negative_regulation (reduced) of Positive_regulation (increase) of IL-6 mRNA
1) Confidence 0.59 Published 2006 Journal Int. Immunopharmacol. Section Abstract Doc Link 16644488 Disease Relevance 0.21 Pain Relevance 0.76
Furthermore, the data suggests that decreasing IL-6 induction of Nox2, or eliminating downstream superoxide production directly can preserve cognitive performance.
Negative_regulation (decreasing) of Positive_regulation (induction) of IL-6 associated with cognitive disorder
2) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2678193 Disease Relevance 0.31 Pain Relevance 0.05
RT-PCR experiments demonstrated that U50,488 treatment significantly reduced the LPS-mediated increase in IL-6 mRNA and that this effect was also blocked by nor-BNI.
Negative_regulation (reduced) of Positive_regulation (increase) of IL-6 mRNA
3) Confidence 0.43 Published 2006 Journal Int. Immunopharmacol. Section Abstract Doc Link 16644488 Disease Relevance 0.21 Pain Relevance 0.76
Accordingly, a very recent study describes reduced body weight under chronically elevated IL-6 levels (41).
Negative_regulation (reduced) of Positive_regulation (elevated) of IL-6 in body associated with body weight
4) Confidence 0.36 Published 2008 Journal Diabetes Section Body Doc Link PMC2584126 Disease Relevance 0.84 Pain Relevance 0.08
PSL-induced upregulation of tumor necrosis factor-alpha and interleukin-6, which are essential for neuropathic pain, was suppressed by pioglitazone for the first week.
Negative_regulation (suppressed) of Positive_regulation (upregulation) of interleukin-6 associated with necrosis, cancer and neuropathic pain
5) Confidence 0.27 Published 2008 Journal J. Pharmacol. Sci. Section Abstract Doc Link 19008646 Disease Relevance 1.55 Pain Relevance 1.56
We tested this hypothesis by generating double mutant mice deficient in both p50 and IL-6, and comparing neutrophil recruitment in double mutants and mice deficient in IL-6 alone. p50 deficiency decreased neutrophil recruitment in the absence of IL-6.
Negative_regulation (decreased) of Positive_regulation (absence) of IL-6 in neutrophil
6) Confidence 0.26 Published 2004 Journal BMC Immunol Section Body Doc Link PMC449706 Disease Relevance 0.26 Pain Relevance 0.23
Treatment with taurine and niacin attenuated the BL-induced increases in proinflammatory cytokines such as IL-1alpha, TNF-alpha, IL-6, and TGF-beta in BALF and lung hydroxyproline content of the mice in BL + TN groups.
Negative_regulation (attenuated) of Positive_regulation (increases) of IL-6 in lung associated with cytokine
7) Confidence 0.23 Published 2000 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 10734156 Disease Relevance 0.29 Pain Relevance 0.21
Meanwhile, cotreatment with ketamine and lipopolysaccharide significantly inhibited lipopolysaccharide-induced TNF-alpha, IL-1beta, and IL-6 mRNA levels.
Negative_regulation (inhibited) of Positive_regulation (lipopolysaccharide-induced) of IL-6 mRNA associated with ketamine
8) Confidence 0.21 Published 2005 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 15781291 Disease Relevance 0.15 Pain Relevance 0.68
However, in our studies, anti-TNF mAb treatment reduced serum IL-6 by a similar magnitude as CP-690550 but did not demonstrate the same degree of efficacy, which suggests the JAK3 inhibitor, affected other inflammatory mediators important for expression of disease in this model.
Negative_regulation (reduced) of Positive_regulation (serum) of IL-6 associated with inflammatory mediators and disease
9) Confidence 0.16 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2374467 Disease Relevance 0.99 Pain Relevance 0.45
On the basis of the evidence that forced expression of SOCS3 can inhibit IL-6-mediated STAT3 activation, we propose that SOCS3 is a negative regulator of inflammatory diseases in synovial fibroblasts, especially in those in which IL-6 levels are very high.
Negative_regulation (inhibit) of Positive_regulation (activation) of IL-6-mediated in fibroblasts associated with inflammation and disease
10) Confidence 0.13 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1174965 Disease Relevance 1.48 Pain Relevance 0.48
In addition to improving clinical outcomes measurements as determined by the American College of Rheumatology (ACR) criteria as early as 1 week after oral administration, R406 also reduced the level of serum IL-6 and MMP-3 (stromelysin-1) in the groups receiving 100?
Negative_regulation (level) of Positive_regulation (serum) of IL-6
11) Confidence 0.09 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2842969 Disease Relevance 0.85 Pain Relevance 0.37
In addition to improving clinical outcomes measurements as determined by the American College of Rheumatology (ACR) criteria as early as 1 week after oral administration, R406 also reduced the level of serum IL-6 and MMP-3 (stromelysin-1) in the groups receiving 100?
Negative_regulation (reduced) of Positive_regulation (serum) of IL-6
12) Confidence 0.09 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2842969 Disease Relevance 0.85 Pain Relevance 0.37
Pretreatment with 1 or 5 µM BAPTA/AM partially inhibited MCP-1 and IL-6, while BAPTA/AM at 10 µM completely abolished production of morphine and Tat-induced increases in MCP-1, IL-6 and TNF-?.
Negative_regulation (abolished) of Positive_regulation (increases) of IL-6 associated with morphine
13) Confidence 0.08 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2605563 Disease Relevance 0 Pain Relevance 0.80
It has also been shown to inhibit MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced interleukin-6 (IL-6), tumor necrosis factor-?
Negative_regulation (inhibit) of Positive_regulation (induced) of interleukin-6 associated with parkinson's disease, necrosis and cancer
14) Confidence 0.08 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 0.53 Pain Relevance 0.18
In synoviocytes, instability of IL-6 mRNA decreases IL-6 protein levels [30].
Negative_regulation (decreases) of Positive_regulation (instability) of IL-6
15) Confidence 0.05 Published 2010 Journal Curr Rheumatol Rep Section Body Doc Link PMC2927688 Disease Relevance 0.84 Pain Relevance 0.50
Fig. 2 showed that C.jejuni-induced IL-12p40 (Fig. 2A) and IL-6 (Fig. 2B) mRNA accumulation was strongly reduced in Bay 11-7085-treated BMDC compared to untreated cells.
Negative_regulation (reduced) of Positive_regulation (accumulation) of IL-6
16) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2760752 Disease Relevance 0.22 Pain Relevance 0.04
Following 3 times of treatment, his clinical symptoms completely disappeared and the increased levels of serum interleukin-6 were decreased to within the normal ranges.
Negative_regulation (decreased) of Positive_regulation (increased) of interleukin-6
17) Confidence 0.03 Published 2003 Journal Clin. Rheumatol. Section Abstract Doc Link 14505222 Disease Relevance 0.89 Pain Relevance 0.25
METHODS: We measured plasma levels of interleukin-1 beta (IL-1beta), tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6) in 97 patients: 67 with stable angina, 24 with unstable angina, and 15 healthy controls.
Negative_regulation (measured) of Positive_regulation (levels) of interleukin 6 in plasma
18) Confidence 0.01 Published 2000 Journal J. Thromb. Thrombolysis Section Body Doc Link 10728019 Disease Relevance 0.19 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox